NCT04948827View on ClinicalTrials.gov

A First-in-Human Study of SBP-9330 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

90

Participants

Timeline

Start Date

July 20, 2021

Primary Completion Date

March 6, 2023

Study Completion Date

March 6, 2023

Conditions

Smoking Cessation

Interventions

DRUG

SBP-9330

SBP-9330 oral capsules

DRUG

Placebo

Placebo oral capsules

Trial Locations (1)

66212

Altasciences Clinical Kansas, Inc, Overland Park

Sponsors

Lead Sponsor

Camino Pharma, LLC

All Listed Sponsors

collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

Sanford Burnham Prebys

OTHER

collaborator

University of California, San Diego

OTHER

lead

Camino Pharma, LLC

INDUSTRY